	Application Number		10555076	
	Filing Date		2006-03-02	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor Taka		agı	
	Art Unit		1627	
	Examiner Name Tin		Firmothy E. Betton	
	Attorney Docket Numb	er	DAISAN126512	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relev Figures Appear	
	1	5130333	A	1992-07-14	Pan			
	2	5298497	A	1994-03-29	Tschollar			
If you wisl	h to ac	d additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS	Remove	
Examiner Initial*		Publication Number		Publication Date	Name of Patentee or Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevan Figures Appear	
If you wis	1 h to ac	d additional U.S. Pub	lished Ap	plication citatio			d button. Add	
				FOREIGN PA	ENI DOCUM	MENIS		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Publication Date	Name of Patente Applicant of cited Document		
	1	0 671 170	EP	A1	1995-09-13	McGovern		
	2	1 325 745	EP	A1	2002-04-18	Kitahara		

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

0956897

EP

Application Number		10555076		
Filing Date		2006-03-02		
First Named Inventor	Takag	Takagı		
Art Unit		1627		
Examiner Name	Timothy E. Betton			
Attomory Docket Number		DAISAN126512		

								_
	4	04-282324	JP	A	1992-10-07	Pan		
	5	20011294526	JP	A	2001-10-23	Sugiyama		
	6	95/13063	wo	A1	1995-05-18	Hirsch		
	7	00/45818	wo	A1	2000-08-10	Cameron		
	8	02/30425	wo	A1	2002-04-18	Kitahara		
	9	2004/052368	wo	A1	2004-06-24	Ohisson		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher, did not country where publisher.						
	1	BALLANTYNE, C.M., et al., "Efficacy of Rosuvastatin 10 mg in Patients With the Metabolic Syndrome," American Journal of Cardiology 91(5A) 25C–27C, March 2003.						
	2	DEEDIVANIA, P. and D. HANNING-HAKE: "Comparative Effects of Statins on Alteragence Dysignations in Patients With the Michable's Syndrome," Journal of the American College of Cardinology 4(5), Specif, A4654, March 2004 (presented at the Stoft Annual Scientific Session of the American College of Cardinology, New Orleans, March 7–10, 2004) (Abstract 200-1).						

1999-11-17 Liebel

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10555076		
Filing Date		2006-03-02		
First Named Inventor	Takag	Takagı		
Art Unit		1627		
Examiner Name	Timothy E. Betton			
Attender Dealest Number		DAICANAGERG		

3	DROSSOS, T., et al., "Results of Pravastatin on Metabolic Parameters of Patients With Diabetes Melitus Type II Under Simultaneous Treatment With Glybenclaimide," Atheroscierosis 144 205, May 1999 (Abstract).	
4	GIANNOUKAKIS, N., and P.D. ROBBINS, "Gene and Cell Therapies for Diabetes Mellinus," Blodrugs 16(3):149-173, 2002.	
5	HOMKO, C.J., et al., "Effects of Free Fatty Acids on Glucose Uptake and Utilization in Healthy Women," Diabetes 52(2):487-491, February 2003.	
6	HUNNINGHAKE, D.B., et al., "Comparative Effects of Simusstatin and Atonesiatin in Hypercholesterolemic Patients With Characteristics of Metabolic Syndrome," Clinical Therapeutics 25(6) 1670-1686, June 2003.	
7	INOUE, Y., et al., "A Multi-Centire Study of the Efficacy and Safety of Pravastatin in Hypercholesteroleemic Patients With Non-Insulin-Dependent Diabetes Meillius," Current Medical Research and Opinion 13(4):187-194, 1994.	
8	MERRILL, G.F., et al., "AICA Riboside increases AMP-Activated Proten Kinase, Fatty Acid Oxidation, and Glucose Uptake in Rat Muscle," American Physiological Society 273(6 Pt 1):E1107–E1112, December 1997.	
9	NEWMAN, C., et al., "Efficacy of Atomastatin in Dystipidemic Patients With Metabolic Syndrome in the ACCESS Study," Diabeties 52(Suppl 1):A494, 2003 (presented at the 63rd Scientific Sessions of the American Diabetes Association, New Orleans, June 13–17, 2003) (Abstract 2141-PO).	
10	OLSSON, A.G., et al., "Rosuvasiatin: A Highly Effective New HMMG-CoA Reductase Inhibitor," Cardiovascular Drug Reviews 20(4) 303–328, January 2002.	
11	PANIAGUA, J.A., et al., "Cerivastatin Improves Insulin Sensitivity and Insulin Secretion in Early-State Obese Type 2 Diabetes," Duabetes 51(8):2566-2603, August 2002.	
12	SUGIMOTO, T., "Pravaslatin Versus Simvaslatin in Hyperlipidemic Patients With Type 2 Diabetes Melitus," Current Therapeutic Research 60(7) 404-413, July 1999.	
13	VAZQUEZ, M., et al., "Experimental Approaches to Study PPARy Agenists as Antidiabetic Drugs," Methods and Findings in Experimental and Clinical Pharmacology 24(8):515-323, October 2002.	

## 

	14	ZHANG, B., et al., "Discovery of a Small Molecule Insulin Milmelic With Antidiabetic Activity in Mice," Science 824(5416) 974–977, May 1999.	
	15	Supplementary European Search Report dated July 8, 2009, in corresponding European Application No. EP 04 72 9769, filed April 27, 2004.	
If you wis	h to a	dd additional non-patent literature document citation information please click the Add button Add	

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTD Patent Documents at were <u>USPTD\_GDY</u> or <u>MPEP 991.64</u>. If Enter office that issued the document, by the two-inter code (WIPD Standard ST.3). First <u>Imparent patent</u> the sensal number of the patent document.

Sendand ST.3. First <u>Imparent patent</u> preced in the sensal number of the patent document.

Sendand ST.3. First <u>Imparent patent</u> preced in the sensal number of the patent document.

Sendand ST.3. First <u>Imparent patent</u> preced in the sensal number of the patent document.

Sendand ST.3. First <u>Imparent patent</u> preceding the patent paten